DK0831910T3 - Kombinationsterapi med epoxy-steroid aldosteronantagonist og angiotensin II-receptorantagonist til behandling af kongestivt hjertesvigt - Google Patents

Kombinationsterapi med epoxy-steroid aldosteronantagonist og angiotensin II-receptorantagonist til behandling af kongestivt hjertesvigt

Info

Publication number
DK0831910T3
DK0831910T3 DK96919170T DK96919170T DK0831910T3 DK 0831910 T3 DK0831910 T3 DK 0831910T3 DK 96919170 T DK96919170 T DK 96919170T DK 96919170 T DK96919170 T DK 96919170T DK 0831910 T3 DK0831910 T3 DK 0831910T3
Authority
DK
Denmark
Prior art keywords
angiotensin
treatment
antagonist
heart failure
combination therapy
Prior art date
Application number
DK96919170T
Other languages
Danish (da)
English (en)
Inventor
John C Alexander
Joseph R Schuh
Richard J Gorczynski
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Application granted granted Critical
Publication of DK0831910T3 publication Critical patent/DK0831910T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK96919170T 1995-06-07 1996-06-05 Kombinationsterapi med epoxy-steroid aldosteronantagonist og angiotensin II-receptorantagonist til behandling af kongestivt hjertesvigt DK0831910T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48645695A 1995-06-07 1995-06-07
PCT/US1996/009335 WO1996040257A1 (en) 1995-06-07 1996-06-05 Epoxy-steroidal aldosterone antagonist and angiotensin ii antagonist combination therapy for treatment of congestive heart failure

Publications (1)

Publication Number Publication Date
DK0831910T3 true DK0831910T3 (da) 2002-05-21

Family

ID=23931955

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96919170T DK0831910T3 (da) 1995-06-07 1996-06-05 Kombinationsterapi med epoxy-steroid aldosteronantagonist og angiotensin II-receptorantagonist til behandling af kongestivt hjertesvigt

Country Status (21)

Country Link
US (1) US6653306B1 (zh)
EP (1) EP0831910B1 (zh)
JP (1) JPH11507627A (zh)
KR (1) KR100618466B1 (zh)
CN (2) CN1142793C (zh)
AT (1) ATE209047T1 (zh)
AU (1) AU725689B2 (zh)
BR (1) BR9609066A (zh)
CA (1) CA2224079A1 (zh)
CZ (1) CZ297975B6 (zh)
DE (1) DE69617235T2 (zh)
DK (1) DK0831910T3 (zh)
ES (1) ES2167571T3 (zh)
IL (1) IL122242A (zh)
NO (1) NO318184B1 (zh)
NZ (1) NZ310730A (zh)
PL (1) PL185150B1 (zh)
PT (1) PT831910E (zh)
RO (1) RO118046B1 (zh)
RU (1) RU2166330C2 (zh)
WO (1) WO1996040257A1 (zh)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6201002B1 (en) 1997-01-10 2001-03-13 Merck & Co., Inc. Method for reducing mortality with an angiotensin II antagonist
IL130599A0 (en) * 1997-01-10 2000-06-01 Merck & Co Inc Use of angiotensin II antagonists to treat symptomatic heart failure
US6306826B1 (en) 1997-06-04 2001-10-23 The Regents Of The University Of California Treatment of heart failure with growth hormone
IL145237A0 (en) * 1999-03-05 2002-06-30 Searle & Co Combination therapy of angiotensin converting enzyme inhibitor and epoxy-steroidal aldosterone antagonist for treatment of cardiovascular disease
US6211217B1 (en) 1999-03-16 2001-04-03 Novartis Ag Method for reducing pericardial fibrosis and adhesion formation
US20030083342A1 (en) * 2002-08-27 2003-05-01 Steele Ronald Edward Combination of organic compounds
US20020132001A1 (en) * 2000-05-11 2002-09-19 Garthwaite Susan M. Aldosterone antagonist composition for release during aldosterone acrophase
EP1303308B1 (en) * 2000-07-27 2006-09-06 Pharmacia Corporation Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders
JP2004505061A (ja) * 2000-07-27 2004-02-19 ファルマシア・コーポレーション うっ血性心不全の処置のための、エポキシ−ステロイド型アルドステロン拮抗薬とカルシウムチャンネル遮断薬の併用療法
JP5082033B2 (ja) 2001-12-21 2012-11-28 エグゼリクシス パテント カンパニー エルエルシー Ｌｘｒのモジュレーター
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
DE60308337T2 (de) * 2002-03-15 2007-09-20 Novartis Ag 4-(4-Methylpiperazin-1-ylmethyl)-N-(4-methyl-3-(4-pyrimidin-3-yl)pyrimidin-2-ylamino)phenylbenzamid zur Behandlung von Ang II vermitteltern Erkrankungen
CL2004000545A1 (es) * 2003-03-18 2005-01-28 Pharmacia Corp Sa Organizada B Uso de un antagonista de los receptores de aldosterona y un antagonista de receptores de endotelina para el tratamiento o profilaxis de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopatia y enfermedades cardiovascul
US20050153885A1 (en) * 2003-10-08 2005-07-14 Yun Anthony J. Treatment of conditions through modulation of the autonomic nervous system
WO2005039637A2 (en) * 2003-10-17 2005-05-06 Novartis Ag Combinations of an aldosterone receptor antagonist, a diuretic and an angiotensin blocker
PL1750862T3 (pl) 2004-06-04 2011-06-30 Teva Pharma Kompozycja farmaceutyczna zawierająca irbesartan
US8569277B2 (en) 2004-08-11 2013-10-29 Palo Alto Investors Methods of treating a subject for a condition
US9512125B2 (en) 2004-11-19 2016-12-06 The Regents Of The University Of California Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
CN101024643A (zh) * 2006-02-20 2007-08-29 上海艾力斯医药科技有限公司 咪唑－5－羧酸类衍生物、制备方法及其应用
CA2647391C (en) 2006-04-04 2015-12-29 The Regents Of The University Of California Kinase antagonists
US20110160232A1 (en) 2007-10-04 2011-06-30 Pingda Ren Certain chemical entities and therapeutic uses thereof
KR101897881B1 (ko) 2008-01-04 2018-09-12 인텔리카인, 엘엘씨 특정 화학 물질, 조성물 및 방법
US8193182B2 (en) * 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
WO2009114874A2 (en) 2008-03-14 2009-09-17 Intellikine, Inc. Benzothiazole kinase inhibitors and methods of use
US8637542B2 (en) 2008-03-14 2014-01-28 Intellikine, Inc. Kinase inhibitors and methods of use
WO2010006072A2 (en) 2008-07-08 2010-01-14 The Regents Of The University Of California Mtor modulators and uses thereof
CN102124009B (zh) 2008-07-08 2014-07-23 因特利凯公司 激酶抑制剂及其使用方法
US8703778B2 (en) 2008-09-26 2014-04-22 Intellikine Llc Heterocyclic kinase inhibitors
WO2010045542A2 (en) 2008-10-16 2010-04-22 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
RS53012B (en) 2009-01-30 2014-04-30 Takeda Pharmaceutical Company Limited CONDENSED RING UNIT AND ITS USE
JP5789252B2 (ja) 2009-05-07 2015-10-07 インテリカイン， エルエルシー 複素環式化合物およびその使用
WO2011047384A2 (en) 2009-10-16 2011-04-21 The Regents Of The University Of California Methods of inhibiting ire1
EP2571357B1 (en) 2010-05-21 2016-07-06 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
WO2012064973A2 (en) 2010-11-10 2012-05-18 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8809349B2 (en) 2011-01-10 2014-08-19 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
US9295673B2 (en) 2011-02-23 2016-03-29 Intellikine Llc Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
CN103930422A (zh) 2011-07-19 2014-07-16 无限药品股份有限公司 杂环化合物及其用途
JP6027611B2 (ja) 2011-07-19 2016-11-16 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環式化合物及びその使用
AU2012302197B2 (en) 2011-08-29 2016-01-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
MX370814B (es) 2011-09-02 2020-01-08 Univ California Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
US8809372B2 (en) 2011-09-30 2014-08-19 Asana Biosciences, Llc Pyridine derivatives
US9199975B2 (en) 2011-09-30 2015-12-01 Asana Biosciences, Llc Biaryl imidazole derivatives for regulating CYP17
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
AU2013323426A1 (en) 2012-09-26 2015-04-23 The Regents Of The University Of California Modulation of ire1
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP6466924B2 (ja) 2013-10-04 2019-02-06 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環式化合物及びその使用
DK3119397T3 (da) 2014-03-19 2022-03-28 Infinity Pharmaceuticals Inc Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
KR20180058741A (ko) 2015-09-14 2018-06-01 인피니티 파마슈티칼스, 인코포레이티드 이소퀴놀리논의 고체형, 그의 제조 방법, 이를 포함하는 조성물 및 이를 사용하는 방법
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA3028718A1 (en) 2016-06-24 2017-12-28 Infinity Pharmaceuticals, Inc. Combination therapies
TW201811759A (zh) 2016-06-29 2018-04-01 加拿大蒙特利爾大學 二芳基甲基雜環
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
US11982483B2 (en) 2021-08-20 2024-05-14 Pioneer Family Brands, Inc. Ice shaver with multi-link control arm
US11971205B2 (en) 2021-08-20 2024-04-30 Pioneer Family Brands, Inc. Ice shaver with splash guard

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI77669C (fi) * 1983-04-13 1989-04-10 Ciba Geigy Ag 20-spiroxaner och analoger, som innehaoller en oeppen ring e, foerfarande foer deras framstaellning samt dessa innehaollande farmaceutiska preparat.
US4880804A (en) * 1988-01-07 1989-11-14 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking benzimidazoles
CA2053148A1 (en) * 1990-10-16 1992-04-17 Karnail Atwal Dihydropyrimidine derivatives
US5049565A (en) * 1990-12-07 1991-09-17 Merck & Co., Inc. Microbial transformation process for preparing anti-hypertensive products
WO1992020662A1 (en) * 1991-05-10 1992-11-26 Merck & Co., Inc. Acidic aralkyl triazole derivatives active as angiotensin ii antagonists
US6008210A (en) * 1992-04-21 1999-12-28 Weber; Karl T. Use of aldosterone antagonists to inhibit myocardial fibrosis
US5529992A (en) * 1992-04-21 1996-06-25 Curators Of The University Of Missouri Method for inhibiting myocardial fibrosis by administering an aldosterone antagonist which suppresses aldoster one receptors
AU5449194A (en) * 1992-10-26 1994-05-24 Merck & Co., Inc. Combinations of angiotensin-ii receptor antagonists and diuretics
CA2125251C (en) * 1993-06-07 2005-04-26 Yoshiyuki Inada A pharmaceutical composition for angiotensin ii-mediated diseases

Also Published As

Publication number Publication date
CZ297975B6 (cs) 2007-05-09
KR19990022548A (ko) 1999-03-25
NO975741D0 (no) 1997-12-05
DE69617235D1 (de) 2002-01-03
IL122242A (en) 2001-07-24
CN1192697A (zh) 1998-09-09
CA2224079A1 (en) 1996-12-19
IL122242A0 (en) 1998-04-05
PL185150B1 (pl) 2003-03-31
ATE209047T1 (de) 2001-12-15
US6653306B1 (en) 2003-11-25
ES2167571T3 (es) 2002-05-16
CZ385097A3 (cs) 1998-06-17
PL324001A1 (en) 1998-04-27
RO118046B1 (ro) 2003-01-30
RU2166330C2 (ru) 2001-05-10
NO975741L (no) 1998-01-29
NZ310730A (en) 2001-01-26
EP0831910A1 (en) 1998-04-01
PT831910E (pt) 2002-05-31
NO318184B1 (no) 2005-02-14
DE69617235T2 (de) 2002-07-25
JPH11507627A (ja) 1999-07-06
EP0831910B1 (en) 2001-11-21
KR100618466B1 (ko) 2006-12-13
AU6157796A (en) 1996-12-30
BR9609066A (pt) 1999-01-26
CN1522701A (zh) 2004-08-25
CN1142793C (zh) 2004-03-24
WO1996040257A1 (en) 1996-12-19
AU725689B2 (en) 2000-10-19

Similar Documents

Publication Publication Date Title
DK0831910T3 (da) Kombinationsterapi med epoxy-steroid aldosteronantagonist og angiotensin II-receptorantagonist til behandling af kongestivt hjertesvigt
DK0831911T3 (da) Kombinationsterapi til behandling af kongestivt hjertesvigt med spironolacton og angiotensin II-antagonist
PL331091A1 (en) Therapeutic multispecific compounds encompassing antibodies against the fcalpha receptor
MY116130A (en) Treatment of upper airway allergic responses
DK0833839T3 (da) Heterocykliske peptidylforbindelser, der er nyttige til behandling af thrombinrelaterede sygdomme
SE9701121D0 (sv) Implantable heart stimulator
DE60120982D1 (de) Epoxy-steroidaler aldosteronantagonist und beta-adrenergischer antagonist-kombinationstherapie zur behandlung von kongestivem herzversagen
DK0951282T3 (da) Forebyggelse og behandling af skeletlidelse med EP2-receptorsubtype-selektive prostaglandin E2-agonister
AU8534291A (en) Renal-selective angiotensin ii antagonists for treatment of hypertension
AU3745795A (en) Use of CCK-B receptor antagonists for the treatment of sleepdisorders
DK1382351T3 (da) Kombinationsterapi med angiotensinomdannende enzyminhibitor og epoxysteroidal aldosteronantagonist til behandling af cardiovaskulær sygdom
NO932391D0 (no) Angiotensin-ii reseptorantagonister for behandling av hjerterytmeforstyrrelser
DK0966282T3 (da) Anvendelse af angiotensin ll antagonister til behandling af symptomatisk hjerteinsufficiens
BG103859A (en) The use of 1-ar(alk)yl-imidazolin-2-on for the treatment of fear and stress conditions
AU2003202486A1 (en) Epoxy-steroidal aldosterone antagonist and angiotensin II antagonist combination therapy for the treatment of congestive heart failure
NO955056L (no) Enantiomerer av 4-(5-fluor-2,3-dihydro-1H-inden-2-yl)-1H-imidazol
DK0927027T3 (da) Anvendelse af 5-HT4-antagonister til regulering af corticosteroid-sekretionen
BR9607612A (pt) Terapia de combinaç o de inibidor de enzima de conversão de angiotensina quantidade de reduzido efeito colateral de antagonista da aldosterona e diurético par tratamento de doenças cardiovasculares
ATE200983T1 (de) Verwendung von lithiumverbindungen zur behandlung von herzinsuffizienz
MX9709978A (es) Terapia de combinacion de antagonista de aldosterona epoxi-esteroidal y antagonista de angiotensina ii para tratamiento de insuficiencia cardiaca congestiva.
IT1241456B (it) Associazione medicamentosa per il trattamento dell'ipertensione e dell'insufficienza cardiaca congestiva. (caso 100-7516)
UA10257A (uk) Спосіб фізіотерапевтичного впливу на організм людини
MX9709976A (es) Terapia de combinacion con espironolactona y antagonista de angiotensina ii para el tratamiento de fallas cardiacas congestivas.
NZ507875A (en) Dressing with anchor structures connected to elastic material which is connected to treatment section
MX9603999A (es) Tratamiento de nefropatia diabetica con valsartan.